Literature DB >> 2723123

Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.

P Gardiner1, K Schrode, D Quinlan, B K Martin, D R Boreham, M S Rogers, K Stubbs, M Smith, A Karim.   

Abstract

Metabolism of spironolactone in man is extensive and complex. For many years the dethioacetylated metabolite, canrenone, was assumed to be the major metabolite. However, recent studies using specific high performance liquid chromatography (HPLC) have demonstrated the presence of spironolactone and the sulfur-containing metabolites 7 alpha-thiomethylspirolactone (IV) and 6 beta-hydroxy-7 alpha-thiomethylspirolactone (V), in addition to canrenone, in the serum after a single oral dose of spironolactone. The importance of spironolactone and metabolites IV and V relative to canrenone at steady state remains unknown and was the subject of the present investigation. Twelve healthy males received 100 mg spironolactone, once daily, for 15 days. Repeated blood samples were taken on days 1, 8 and 15 for estimation of spironolactone and its metabolites. Peak serum levels [mean (SD)] of spironolactone, canrenone, and sulfur-containing metabolites IV and V were 72 (45), 155 (43), 359 (106) and 101 (26) ng/ml, respectively on day 1 and 80 (20), 181 (39), 391 (118) and 125 (24) ng/ml, respectively on day 15. The AUC (0-24) values of these compounds on day 15 were 231 (50), 2173 (312), 2804 (777) and 1727 (367) ng.hr/ml, respectively and the post-steady state elimination half-life (t1/2) values were 1.4 (0.5), 16.5 (6.3), 13.8 (6.4), and 15.0 (4.0) hours, respectively. It was concluded that unmetabolized spironolactone is present in the serum and that the sulfur-containing metabolite IV rather than canrenone is the major metabolite in serum following single or repeated doses of spironolactone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723123     DOI: 10.1002/j.1552-4604.1989.tb03339.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  34 in total

1.  Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response.

Authors:  Ayala Gold; Lital Eini; Malka Nissim-Rafinia; Ruth Viner; Shlomit Ezer; Keren Erez; Nasma Aqaqe; Rotem Hanania; Michael Milyavsky; Eran Meshorer; Michal Goldberg
Journal:  Oncogene       Date:  2019-01-08       Impact factor: 9.867

Review 2.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 3.  Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.

Authors:  Mohammed I Danjuma; Ipshita Mukherjee; Janine Makaronidis; Serge Osula
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

4.  Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors:  Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

Review 5.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 6.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

7.  The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency.

Authors:  Luisa Mori; Katharine Jenike; Yang-Hui Jimmy Yeh; Benoît Lacombe; Chuan Li; Adam Getzler; Sonia Mediouni; Michael Cameron; Matthew Pipkin; Ya-Chi Ho; Bertha Cecilia Ramirez; Susana Valente
Journal:  J Virol       Date:  2020-11-25       Impact factor: 5.103

8.  Aldosterone-receptor antagonism and end-stage renal disease.

Authors:  Niall McLaughlin; Todd W B Gehr; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

9.  Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.

Authors:  Dinesh Verma; Jacob Thompson; Sankar Swaminathan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

Review 10.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.